RxDoctor Payments Data

Kathleen Gallaher, MD

Family Medicine · Villa Park, CANPI 1114034808

Payments from drug & device makers

$1,202in general payments, 2019–2025

Across 42 payments — averaging $28.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$341
  • Merz North America, Inc.$293
  • Pfizer$139
  • Therapeuticsmd, Inc.$129
  • AstraZeneca$117
  • Boehringer Ingelheim$29
  • plus $153 from 8 others

What the payments were for

  • Food & beverage$1,196100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,202 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$37,252
Medicare patients
136
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$57,294
EliquisApixaban26$27,743
JardianceEmpagliflozin19$26,081
SynthroidLevothyroxine Sodium51$5,218
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$2,584
Levothyroxine Sodium153$2,107
Rosuvastatin Calcium82$1,545
Atorvastatin Calcium143$1,360
Omeprazole58$929
Gabapentin37$918
Estradiol35$857
Olmesartan Medoxomil22$821
Losartan Potassium86$768
ValacyclovirValacyclovir Hcl15$744
Metoprolol Succinate59$658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$17$57,29452 claims
PfizerEliquis$139$27,74326 claims
Boehringer IngelheimJardiance$29$26,08119 claims
AbbVieSynthroid$341$5,21851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Villa Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →